Imago BioSciences’ Bomedemstat Demonstrates Continued Encouraging Clinical Activity in Phase 2 Data for Treatment of Essential Thrombocythemia and Myelofibrosis at EHA 2021 Virtual Congress

SOUTH SAN FRANCISCO, Calif. – June 11, 2021 – Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today provided updates on two Phase 2 clinical trials

Imago BioSciences Appoints Wan-Jen Hong, M.D., as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif. — June 3, 2021 –(BUSINESS WIRE)– Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Wan-Jen Hong, M.D., as chief medical officer.

Read More

Imago BioSciences to Present Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at 2021 European Hematology Association Virtual Congress

South San Francisco, CA, May 21, 2021 — Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that updated Phase 2 data from its two clinical programs

Imago BioSciences to Participate in Upcoming Investor Conferences

South San Francisco, Calif. – Feb. 9, 2021 – Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that

Imago BioSciences Appoints Enoch Kariuki to Board of Directors

South San Francisco, Calif. – Feb. 2, 2021 – Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that

Imago BioSciences Appoints Matthew J. Plunkett as Chief Financial Officer

South San Francisco, Calif. – January 19, 2021 – Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced the appointment

Imago BioSciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

South San Francisco, CA, – January 12, 2021 – Imago BioSciences, Inc., a clinical-stage biopharmaceutical company developing innovative treatments for myeloproliferative neoplasms, today announced that